L
Lee-Anne Stayner
Researcher at Princess Margaret Cancer Centre
Publications - 9
Citations - 266
Lee-Anne Stayner is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Tolerability & Trametinib. The author has an hindex of 5, co-authored 9 publications receiving 217 citations.
Papers
More filters
Journal ArticleDOI
Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas.
Anastasios Stathis,Sebastien J. Hotte,Eric X. Chen,H. Hirte,Amit M. Oza,Patricia Moretto,Sheila Webster,Anne Laughlin,Lee-Anne Stayner,Shauna McGill,Lisa Wang,Wenjiang Zhang,Igor Espinoza-Delgado,Julianne L. Holleran,Merrill J. Egorin,Lillian L. Siu +15 more
TL;DR: The combination of decitabine with vorinostat is tolerable on both concurrent and sequential schedules in previously treated patients with advanced solid tumors or non-Hodgkin's lymphomas and the sequential schedule was easier to deliver.
Journal ArticleDOI
A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors
Juneko E. Grilley-Olson,Philippe L. Bedard,Angelica Fasolo,Cornfeld Mark J,Cornfeld Mark J,Cornfeld Mark J,Leanne Cartee,Leanne Cartee,Albiruni Ryan Abdul Razak,Lee-Anne Stayner,Yuehui Wu,Yuehui Wu,R. Greenwood,R. Greenwood,R. Greenwood,Rajeshwar Singh,Rajeshwar Singh,Carrie B. Lee,Johanna C. Bendell,H. A. Burris,G. Del Conte,Cristiana Sessa,J. R. Infante +22 more
TL;DR: GSK458 plus trametinib is poorly tolerated, due to skin and GI-related toxicities, which may be due to overlapping toxicities precluding sufficient dose exposure.
Journal ArticleDOI
Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials.
Yada Kanjanapan,Yada Kanjanapan,Daphne Day,Daphne Day,Marcus O. Butler,Marcus O. Butler,Lisa Wang,Anthony M. Joshua,Anthony M. Joshua,David Hogg,David Hogg,Natasha B. Leighl,Natasha B. Leighl,Albiruni Ryan Abdul Razak,Albiruni Ryan Abdul Razak,Aaron R. Hansen,Aaron R. Hansen,S. Boujos,Maryanne Chappell,K. Chow,B. Sherwin,Lee-Anne Stayner,L. Soultani,Aaron Zambrana,L.L. Siu,L.L. Siu,Philippe L. Bedard,Anna Spreafico,Anna Spreafico +28 more
TL;DR: The risk of csAE was highest during the initial 4 weeks on IO treatment, supporting the use of the conventional DLT period for dose escalation decision, and combination IO was associated with greater risk of and also earlier onset for csAE, which may need to be considered for early phase trial design.
Journal ArticleDOI
A phase I trial of two sequence-specific schedules of decitabine and vorinostat in patients with acute myeloid leukemia
Jonathan How,Mark D. Minden,Leber Brian,Eric Chen,Joseph Brandwein,Andre C. Schuh,Aaron D. Schimmer,Vikas Gupta,Sheila Webster,Tammy Degelder,Patricia Haines,Lee-Anne Stayner,Shauna McGill,Lisa Wang,Richard Piekarz,Tracy S. Wong,Lillian L. Siu,Igor Espinoza-Delgado,Julianne L. Holleran,Merrill J. Egorin,Karen W.L. Yee +20 more
TL;DR: Decitabine plus vorinostat was safe and has clinical activity in patients with previously untreated acute myeloid leukemia and Responses appear higher with the concurrent dose schedule.
Journal ArticleDOI
A phase II trial of GSK2256098 and trametinib in patients with advanced pancreatic ductal adenocarcinoma (PDAC) (MOBILITY-002 Trial, NCT02428270).
Kyaw L. Aung,Elaine McWhirter,Stephen Welch,Lisa Wang,Sophia Lovell,Lee-Anne Stayner,Saara Ali,Anne Malpage,Barbara Makepeace,Makilpriya Ramachandran,Neesha C. Dhani,David W. Hedley,Jennifer J. Knox,Lillian L. Siu,Rachel Anne Goodwin,Philippe L. Bedard +15 more
TL;DR: MEK (mitogen-activated protein kinase kinase) is activated through mutated KRAS in > 90% of PDAC and Focal adhesion kinase (FAK) integrates signals from integrins and growth factor recipients.